La vendita allo scoperto per Allarity Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Allarity Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Allarity Therapeutics (NASDAQ:ALLR) Azioni, Report sulle vendite allo scoperto

Allarity Therapeutics

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Tesla Rival XPeng Eyes $13.8 Billion Investment In Humanoid Robots, Says Chinese State Media

Equities

Market Summary

News

Pre-Market Outlook

Markets

Trading Ideas

ALLR

NCNO

SPWH

ULBI

XPEV

Nonostante le previsioni negative sui mercati, alcune società hanno registrato performance promettenti. Ecco di chi si tratta.

XPeng, Ultralife e altre 3 azioni da tenere d&#39;occhio in vista di martedì

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics Inc

Allreal Holding Ltd

Recently disclosed clinical cohort data from high (1x1015&nbsp;total vg) and low dose (5.7x1014&nbsp;total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials
Caregiver research regarding gain/regain of developmental milestones supporting alignment with FDA on primary endpoint in the pivotal Part B trial of TSHA-102
Previously disclosed preclinical data supporting broad biodistribution across brain and spinal cord regions following lumbar intrathecal delivery of AAV9 gene therapy vectors in non-human primates
Symposium on Rett syndrome natural history data findings
DALLAS, June 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced details for three oral presentations reviewing recent updates supporting its TSHA-102 program in clinical evaluation for Rett syndrome, and a Taysha-hosted symposium on the Company's analysis of the natural history study data at the 2025 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting, taking place in&nbsp;Boston from&nbsp;June 9-11, 2025. The three presentations will also be presented during a poster session on Monday, June 9, 2025, from 5:00-7:00 PM EST. Additional details on the meeting can be found at IRSF's <a href="https://www.globenewswire.com/Tracker?data=fRcesPdJZ6naTCRmA1KdBnqknjMPiqUOSAZbibyIduSLIZBHD1sKDusevNNC9IDpOhcz49wKMcjwGxoZlu3UJQq_yJHoYjp2wi2ObKNmW3dZm0YC9_b3FmpZWcqr8vQ-RiqQI0N_8TElkfU9BZ2OAajR6CbuQwJ7QUjVqGCV5og=">website</a>.

Biotech

General

TSHA

Taysha Gene Therapies To Present Clinical And Preclinical Data Supporting TSHA-102 Rett Syndrome Program, Including Dose Cohort Results, Caregiver Insights Aligning With FDA Endpoints, At IRSF Scientific Meeting June 9–11, 2025 In Boston

Offerings

LUCD

Lucid Diagnostics Files For Offering Of 36M Shares Of Common Stock

Lumentum Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) shares are rising in extended trading on Tuesday after the company updated its guidance for the current quarter ahead of a <a href="https://www.benzinga.com/topic/bofa">scheduled presentation this week</a>.
What Happened: After the market close on Tuesday, Lumentum said it now expects fourth-quarter revenue of $465 million to $475 million, up from prior guidance of $440 million to $470 million.
The company noted that it expects to achieve $500 million of revenue in the first quarter of fiscal 2026, a quarter earlier than previously planned. 
Lumentum also raised its fourth-quarter earnings guidance from a range of 70 cents to 80 cents per share to a new range of 78 cents to 85 cents per share. The company said it anticipates a fourth-quarter operating margin of 14% to 15%, up from prior guidance of 13% to 14%.
Lumentum&#8217;s management team will discuss the updated forecast at the BofA Securities 2025 Global Technology Conference&nbsp;on Wednesday. 
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45759307/sportsmans-warehouse-stock-tanks-after-q1-earnings-revenues-miss-details">Sportsman&#8217;s Warehouse Stock Tanks After Q1 Earnings, Revenues Miss: Details</a>
<h1 class="wp-block-heading">How To Buy LITE Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For Lumentum, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
LITE Price Action: Lumentum shares were up 3.67% in after-hours, trading at $80.50 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Guidance

After-Hours Center

Movers

LITE

Lumentum Stock Jumps After The Close On Rosier Outlook

Unitil Corp Files For Stock Shelf; Size Not Disclosed

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) has outperformed the market over the past 5 years by 37.8% on an annualized basis producing an average annual return of 50.82%. Currently, Axon Enterprise has a market capitalization of $59.09 billion. 
Buying $100 In AXON: If an investor had bought $100 of AXON stock 5 years ago, it would be worth $818.05 today based on a price of $759.07 for AXON at the time of writing.
<h3>Axon Enterprise's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748985312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXON

$100 Invested In Axon Enterprise 5 Years Ago Would Be Worth This Much Today

CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.66 by 10.61 percent. This is a 7.59 percent decrease over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $1.10 billion which missed the analyst consensus estimate of $1.11 billion by 0.59 percent. This is a 19.80 percent increase over sales of $921.04 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

CRWD

CORRECTION: CrowdStrike Holdings Q1 Adj. EPS $0.73 Beats $0.66 Estimate, Sales $1.10B Miss $1.11B Estimate

WIIM

SPWH stock has given up its prior loss. Sportsman's Warehouse shares were trading lower after the company reported worse-than-expected Q1 financial results.

Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.33 by 15.15 percent. This is a 9.52 percent decrease over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $7.63 billion which beat the analyst consensus estimate of $7.50 billion by 1.69 percent. This is a 5.87 percent increase over sales of $7.20 billion the same period last year.

CORRECTION: Hewlett Packard Q2 Adj. EPS $0.38 Beats $0.33 Estimate, Sales $7.63B Beat $7.50B Estimate

HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/06/g45757436/healthequity-reports-first-quarter-ended-april-30-2025-financial-results">details from the report. </a>
The Details: HealthEquity reported quarterly earnings of 97 cents per share, which beat the consensus estimate of 88 cents. Quarterly revenue came in at $330.8 million, beating the Street estimate of $321.17 million.
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
The company reported: 
<ul class="wp-block-list">
<li>9.9 million HSAs, an increase of 9% compared to the first quarter of FY25.</li>
<li>Total HSA Assets of $31.3 billion, an increase of 15% compared to the first quarter of FY25.</li>
<li>17.1 million Total Accounts, including both HSAs and complementary CDBs, an increase of 7% compared to first quarter FY25.</li>
</ul>
&#8220;The HealthEquity team started fiscal 2026 with a strong first quarter that included record quarterly revenue, record Adjusted EBITDA and increased guidance for the year,&#8221; said Scott Cutler, CEO of HealthEquity.
&#8220;We enhanced our member-first secure mobile experience to strengthen the security of our members&#8217; $31 billion of HSA Assets, increase member resources, and reduce costs.&#8221;
Outlook:&nbsp;HealthEquity raised its fiscal 2026 adjusted EPS guidance from a range of $3.57 to $3.74&nbsp;to&nbsp;a new range of $3.61 to $3.78, versus the&nbsp;$3.63&nbsp;analyst estimate. The company reiterated its 2026 revenue outlook for a range of&nbsp;$1.28 billion to $1.3 billion, versus the $1.3 billion estimate.
HQY Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Health Equity stock was up 5.01% at $108.96 in Tuesday's extended trading.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Image: Shutterstock

Health Care

HealthEquity Shares Trade Higher After Better-Than-Expected Q1 Report: Here's Why

Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $56.52 million which beat the analyst consensus estimate of $55.59 million by 1.68 percent. This is a 10.12 percent increase over sales of $51.33 million the same period last year.

BASE

CORRECTION: Couchbase Q1 Adj. EPS $(0.06) Beats $(0.08) Estimate, Sales $56.52M Beat $55.59M Estimate

EPR Properties: Files For Mixed Shelf Offering; Size Not Disclosed

<h3>Gainers</h3>
<ul>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) shares increased by 33.7% to $2.3 during Tuesday's after-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>Baosheng Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAOS#NASDAQ">BAOS</a>) shares rose 26.14% to $2.99. The market value of their outstanding shares is at $4.5 million. </li>
<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock moved upwards by 17.68% to $0.2. The market value of their outstanding shares is at $2.8 million. </li>
<li>CTRL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCTR#NASDAQ">MCTR</a>) shares moved upwards by 14.74% to $37.75. The company's market cap stands at $577.5 million. </li>
<li>NFT (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MI#AMEX">MI</a>) stock rose 10.08% to $2.62. The market value of their outstanding shares is at $13.2 million. </li>
<li>ZW Data Action Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNET#NASDAQ">CNET</a>) shares moved upwards by 7.51% to $1.43. The company's market cap stands at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GD Culture Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>) stock decreased by 6.0% to $2.65 during Tuesday's after-market session. The market value of their outstanding shares is at $44.5 million. </li>
<li>AirNet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTE#NASDAQ">ANTE</a>) stock decreased by 5.34% to $0.75. The company's market cap stands at $10.7 million. </li>
<li>QMMM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) shares declined by 4.77% to $1.0. The company's market cap stands at $17.2 million. </li>
<li>Brag House Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBH#NASDAQ">TBH</a>) stock declined by 4.74% to $0.56. The market value of their outstanding shares is at $6.0 million. </li>
<li>NIP Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) stock decreased by 3.9% to $1.48. The company's market cap stands at $83.2 million. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) shares decreased by 3.82% to $1.25. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANTE

BAOS

BHAT

BLMZ

CNET

MCTR

NIPG

QMMM

12 Communication Services Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCCP#NASDAQ">CYCCP</a>) stock increased by 29.5% to $5.18 during Tuesday's after-market session. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 9.05% to $5.78. The company's market cap stands at $154.4 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares moved upwards by 6.86% to $0.45. The market value of their outstanding shares is at $19.8 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares rose 6.8% to $0.79. The company's market cap stands at $61.0 million. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) stock moved upwards by 6.48% to $5.68. The company's market cap stands at $268.2 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 6.44% to $0.38. The company's market cap stands at $12.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 15.2% to $0.05 during Tuesday's after-market session. The company's, Q1 earnings came out yesterday. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares fell 12.3% to $5.92. The company's market cap stands at $4.3 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares decreased by 11.35% to $2.5. The company's market cap stands at $6.4 million. </li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares fell 8.27% to $25.3. The market value of their outstanding shares is at $33.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares decreased by 8.21% to $0.35. The market value of their outstanding shares is at $2.0 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock fell 7.63% to $0.73. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDI

CLSD

CYCCP

GTBP

HBIO

LIMN

LYRA

NCNA

PSTV

RSLS

WINT

12 Health Care Stocks Moving In Tuesday's After-Market Session

YIBO

Planet Image International Files For Mixed Shelf Of Up To $100M

<h3>Gainers</h3>
<ul>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares increased by 12.5% to $3.5 during Tuesday's after-market session. The company's market cap stands at $14.7 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock increased by 10.81% to $0.51. The market value of their outstanding shares is at $73.0 million. </li>
<li>Hong Kong Pharma Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKPD#NASDAQ">HKPD</a>) shares rose 6.32% to $1.68. The company's market cap stands at $18.4 million. </li>
<li>ClearSign Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIR#NASDAQ">CLIR</a>) shares rose 5.99% to $0.67. The market value of their outstanding shares is at $35.1 million. </li>
<li>Webus International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) shares rose 5.73% to $2.58. The company's market cap stands at $56.7 million. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) stock rose 5.7% to $2.78. The company's market cap stands at $5.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) stock declined by 7.5% to $0.27 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Conduent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNDT#NASDAQ">CNDT</a>) stock decreased by 6.12% to $2.3. The company's market cap stands at $372.2 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock declined by 5.25% to $1.08. The company's market cap stands at $59.9 million. </li>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) shares decreased by 4.4% to $3.43. The company's market cap stands at $27.3 million. </li>
<li>Haoxin Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HXHX#NASDAQ">HXHX</a>) stock declined by 4.14% to $1.85. The company's market cap stands at $25.4 million. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) stock declined by 3.91% to $1.23. The market value of their outstanding shares is at $26.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLIR

CNDT

HKPD

HXHX

NCEW

Nuveen Insured California Premium Fund Ii

SCWO

SOAR

VCIG

WETO

ZONE

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) shares rose 8.8% to $237.41 during Tuesday's after-market session. The market value of their outstanding shares is at $19.9 billion. The company's, Q3 earnings came out today. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock rose 5.62% to $0.93. The market value of their outstanding shares is at $24.0 million. </li>
<li>Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) shares moved upwards by 5.4% to $81.85. The market value of their outstanding shares is at $5.6 billion. </li>
<li>HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) shares increased by 5.17% to $0.61. The market value of their outstanding shares is at $13.4 million. </li>
<li>Hitek Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKIT#NASDAQ">HKIT</a>) shares moved upwards by 4.79% to $1.53. The company's market cap stands at $44.8 million. </li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock increased by 4.67% to $1.12. The company's market cap stands at $9.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares declined by 6.8% to $17.7 during Tuesday's after-market session. The company's market cap stands at $4.1 billion. As per the news, the Q1 earnings report came out today. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares decreased by 6.55% to $1.0. The company's market cap stands at $25.1 million. </li>
<li>CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) stock fell 6.38% to $457.6. The company's market cap stands at $113.4 billion. The company's, Q1 earnings came out today. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares fell 5.77% to $3.1. The market value of their outstanding shares is at $4.7 million. </li>
<li>Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) shares decreased by 4.12% to $12.83. The company's market cap stands at $515.8 million. </li>
<li>Focus Universal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares declined by 4.0% to $3.85. The company's market cap stands at $27.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASAN

DOMO

FCUV

GWRE

HKIT

HTCR

IFBD

SOBR

12 Information Technology Stocks Moving In Tuesday's After-Market Session

VCI Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) ("VCI Global" or the "Company"), a diversified global holding company with a strategic focus on AI &amp; Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy, today announced its financial guidance for the fiscal year ending December 31, 2025.
For 2025, the Company projects approximately 41% year-over-year revenue growth and 30% year-over-year growth in net profit, fueled by continued expansion across its technology and consulting verticals, alongside the execution of key strategic milestones.
As part of its long-term value creation strategy, VCI Global confirmed plans to carve out and list its capital market consulting arm, V Capital Consulting Group Limited ("VCCG"), via an initial public offering (IPO) targeted for the third quarter of 2025. The IPO is intended to increase visibility for the subsidiary, unlock shareholder value, and provide targeted growth capital to scale VCCG's advisory and IPO execution business.
The Company's 2025 outlook also reflects contributions from several high-growth initiatives, including the commercialization of its encrypted AI data platform, the launch of GPU-as-a-Service infrastructure, and the expansion of its cross-border fintech and energy-related ventures.
&nbsp;
FY2025 Financial Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">FY2024 Results</td>
<td colspan="2">FY2025 Financial Guidance</td>
<td>Change</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">USD</td>
<td colspan="2">USD</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>27,824,891</td>
<td>39,233,096</td>
<td>41</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Cost of Service</td>
<td>4,948,193</td>
<td>7,422,290</td>
<td>50</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>22,876,698</td>
<td>31,810,806</td>
<td>39</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Operating Expenses</td>
<td>(15,433,046</td>
<td>)</td>
<td>(21,712,897</td>
<td>)</td>
<td>41</td>
<td>%</td>
</tr>
<tr>
<td>EBIDTA</td>
<td>9,235,725</td>
<td>12,709,247</td>
<td>38</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net Profit</td>
<td>7,576,827</td>
<td>9,881,076</td>
<td>30</td>
<td>%</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

VCI Global Sees FY25 Revenue Of 39.233M

Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 183.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $187.27 million which beat the analyst consensus estimate of $185.40 million by 1.01 percent. This is a 8.59 percent increase over sales of $172.45 million the same period last year.

CORRECTION: Asana Q1 Adj. EPS $0.05 Beats $0.02 Estimate, Sales $187.27M Beat $185.40M Estimate

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.47 by 87.23 percent. This is a 238.46 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $293.51 million which beat the analyst consensus estimate of $286.39 million by 2.49 percent. This is a 21.95 percent increase over sales of $240.68 million the same period last year.

CORRECTION: Guidewire Software Q3 Adj. EPS $0.88 Beats $0.47 Estimate, Sales $293.51M Beat $286.39M Estimate

Across the recent three months, 4 analysts have shared their insights on LCI Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $90.75, a high estimate of $100.00, and a low estimate of $80.00. This current average represents a 13.16% decrease from the previous average price target of $104.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1748984483_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of LCI Industries among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$88.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to LCI Industries. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of LCI Industries compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for LCI Industries's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into LCI Industries's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LCII/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on LCI Industries analyst ratings.</a>
<h2>All You Need to Know About LCI Industries</h2>
LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.
<h3>Unraveling the Financial Story of LCI Industries</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: LCI Industries displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 8.01%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: LCI Industries's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.73% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.59%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.65%, the company showcases effective utilization of assets.
Debt Management: LCI Industries's debt-to-equity ratio is below the industry average at 0.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

LCII

Where LCI Industries Stands With Analysts

Penny Stocks

Press Releases

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US

Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer

Comments

Allarity Therapeutics

Vendite allo scoperto

Allarity Therapeutics (NASDAQ:ALLR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO